Arix Bioscience Plc - Director/PDMR Shareholding
Updated : 07:01
This regulatory news is for Private Investors only
Arix Bioscience Plc - Director/PDMR Shareholding
PR Newswire
London, May 9
10 May 2019
ARIX BIOSCIENCE PLC
Director/PDMR Shareholding
Arix Bioscience plc today announces the annual award of nil cost options to certain members of management, all of which are subject to performance conditions over a three year assessment period, in accordance with the company’s Remuneration Policy.
| PDMR DEALING NOTIFICATION | |||
| Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them | |||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Joseph Anderson | |
| 2 | Reason for the notification | ||
| a) | Position / status | Chief Executive Officer | |
| b) | Initial notification / Amendment | Initial Notification | |
| 3 | Details of issuer | ||
| a) | Name | Arix Bioscience plc | |
| b) | LEI | 213800OVT3AHQCXNIX43 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of Arix Bioscience plc | |
| Identification code | GB00BD045071 | ||
| b) | Nature of the transaction | Award of nil-cost options under the Arix Bioscience plc Executive Incentive Plan ("EIP") | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | 578,368 | ||
| d) | Aggregated information | Aggregated price | Aggregated volume |
| N/A (single transaction) | N/A (single transaction) | ||
| e) | Date of the transaction | 09 May 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
| PDMR DEALING NOTIFICATION | |||
| Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them | |||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | James Hedley Rawlingson | |
| 2 | Reason for the notification | ||
| a) | Position / status | Chief Financial Officer | |
| b) | Initial notification / Amendment | Initial Notification | |
| 3 | Details of issuer | ||
| a) | Name | Arix Bioscience plc | |
| b) | LEI | 213800OVT3AHQCXNIX43 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of Arix Bioscience plc | |
| Identification code | GB00BD045071 | ||
| b) | Nature of the transaction | Award of nil-cost options under the Arix Bioscience plc Executive Incentive Plan ("EIP") | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | 234,239 | ||
| d) | Aggregated information | Aggregated price | Aggregated volume |
| N/A (single transaction) | N/A (single transaction) | ||
| e) | Date of the transaction | 09 May 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
| PDMR DEALING NOTIFICATION | |||
| Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them | |||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Robert Lyne | |
| 2 | Reason for the notification | ||
| a) | Position / status | Chief Operating Officer | |
| b) | Initial notification / Amendment | Initial Notification | |
| 3 | Details of issuer | ||
| a) | Name | Arix Bioscience plc | |
| b) | LEI | 213800OVT3AHQCXNIX43 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of Arix Bioscience plc | |
| Identification code | GB00BD045071 | ||
| b) | Nature of the transaction | Award of nil-cost options under the Arix Bioscience plc Executive Incentive Plan ("EIP") | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | 195,199 | ||
| d) | Aggregated information | Aggregated price | Aggregated volume |
| N/A (single transaction) | N/A (single transaction) | ||
| e) | Date of the transaction | 09 May 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
For further information:
Robert Lyne Chief Operating Officer +44 (0)207 290 1050
- Ends -